Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. Its Dental Solutions segment provides a suite of dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions and services for health care systems, such as computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is based in Maplewood, Minnesota.

Revenue projections:

Revenue projections for SOLV
Revenue projections for SOLV

SOLV's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.231000
forwardPE 9.552483
debtToEquity 103.941000
earningsGrowth 1.008000
revenueGrowth -0.037000
grossMargins 0.535740
operatingMargins 0.070070
trailingEps 8.880000
forwardEps 6.975150

With a current ratio of 1.231, SOLV has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that SOLV is in a strong position to meet its immediate financial obligations without difficulty.
SOLV's elevated debt-to-equity ratio highlights its heavy reliance on debt. This high leverage increases the company's exposure to financial risk, making it more vulnerable to market fluctuations and economic downturns.
SOLV's forward EPS is less than its trailing EPS, signaling that the company's profitability is expected to shrink. This points to a potential downturn in earnings compared to last year.

Price projections:

Price projections for SOLV
Price projections for SOLV

SOLV's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for SOLV
Insider Transactions for SOLV


1 SOLV transactions were recorded, when the market price was 71.41999816894531.Solventum Corporation had 1 buy transactions, with market price of 67.5999984741211.Investors have been purchasing SOLV more than selling it at current price levels, which may reflect optimism. This pattern suggests that the market expects favorable outcomes for the stock, leading to increased buying interest.

Recommendation changes over time:

Recommendations trend for SOLV
Recommendations trend for SOLV


With analysts showing a buy bias for SOLV, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning SOLV as a safe and profitable place for investors to allocate their funds and seek growth.